Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Topiramate

Plain-language summaryIntrigue 68 / 100

Topiramate (Topamax) is a sugar-derived anticonvulsant from Johnson and Johnson, approved by the FDA in 1996. It hits multiple targets at once: blocks sodium channels, potentiates GABA-A receptors, blocks AMPA glutamate receptors, and inhibits carbonic anhydrase. The mechanistic breadth makes it useful well beyond epilepsy. It is approved for migraine prevention, where it is one of the more effective options. It has substantial off-label use for weight loss because the carbonic anhydrase inhibition produces a metallic taste that suppresses appetite, and for alcohol use disorder where it appears to reduce craving. The side effect signature includes word-finding difficulty (the patient slang is dopamax), tingling in hands and feet, and kidney stone risk. Co-formulated with phentermine as Qsymia for obesity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

Mature multifactorial anticonvulsant with real but narrowly concentrated bench utility in AMPA and glutamate programs

Look, topiramate is a compound that’s been around long enough to earn a nickname. “Dopamax” is what clinicians call it, a reference to the cognitive blunting that causes roughly 40 percent of patients to report word-finding difficulty and slowed mentation. That reputation didnt develop in a vacuum, and it tells you something real about what you’re working with when you put this molecule into a CNS research program.

What we actually find interesting isnt what a prescriber finds interesting. The five-target mechanism, state-dependent sodium channel inhibition, GABA-A potentiation at a non-benzodiazepine site, AMPA/kainate glutamate receptor antagonism, carbonic anhydrase inhibition across isozymes II and IV, and high-voltage calcium channel block, is genuinely unusual for a small molecule. You can source sodium channel blockers easily. GABA-A modulators are everywhere. The AMPA/kainate piece is the angle worth paying attention to, because topiramate remains one of the more pharmacologically accessible probes for AMPA receptor biology available to bench investigators. That has kept it relevant in CNS research programs even as its clinical novelty evaporated.

The evidence quality is not in question. Multiple phase 3 programs, FDA approval across four distinct indications, and decades of multi-site clinical data from populations in the tens of thousands. You dont have to speculate about whether topiramate produces a human signal. The question is whether the signal is interesting, and in most indications the answer is now mostly historical. The weight loss angle was differentiated in the Qsymia era, but GLP-1s have reframed that entire conversation and topiramate isnt competing there anymore.

The one area where current research still generates real signal is alcohol use disorder. Several controlled trials have shown suppression of craving and reduction in heavy drinking days, and the proposed mechanism, glutamatergic dampening of cue-induced salience, is both plausible and relatively underexplored compared to the naltrexone/acamprosate playbook. If your program touches AUD neuroscience or glutamate-driven compulsive behavior, topiramate is worth taking seriously as a reference compound with replicated human data.

We think the bench value is genuine but specific. If the program involves AMPA receptor pharmacology, CNS carbonic anhydrase biology, or glutamatergic contributions to addictive behavior, topiramate earns its place. For anything outside those domains, the cognitive liability and the largely-harvested literature make it a low-priority entry. Score of 50 reflects that kind of concentrated, real-but-narrow research utility: not a frontier compound, not a throwaway.

Novelty

22

Mechanism promise

45

In-category differentiation

45

Evidence quality

75

Translational signal

70

Research bench value

55

Rationale Topiramate’s unusually broad five-target mechanism and robust FDA-backed evidence base are real, but 30 years of thorough characterization suppresses novelty to the floor; the score reflects a compound whose research value is genuine but domain-specific, not frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Sulfamate-substituted monosaccharide / multifactorial anticonvulsant

A sulfamate-substituted monosaccharide anticonvulsant with broad mechanism (sodium channels, GABA-A potentiation, AMPA antagonism, carbonic anhydrase inhibition); used for migraine prophylaxis and weight loss.

Abstract

Topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; CAS 97240-79-4; molecular formula C12H21NO8S; molecular weight 339.36) is a sulfamate-substituted monosaccharide anticonvulsant developed at Johnson and Johnson and approved by the FDA in 1996 under the trade name Topamax. Mechanism is multifactorial: state-dependent sodium channel inhibition; GABA-A receptor potentiation at a non-benzodiazepine site; AMPA/kainate glutamate receptor antagonism; carbonic anhydrase inhibition (isozymes II and IV); high-voltage calcium channel inhibition. The carbonic anhydrase activity contributes to the characteristic adverse events: paresthesias (40 percent of patients), nephrolithiasis (1.5 percent), metabolic acidosis. Cognitive side effects are pronounced: word-finding difficulty, slowed mentation. Plasma half-life is 21 hours; metabolism is approximately 70 percent renal excretion unchanged. Approved for partial-onset and generalized tonic-clonic seizures, Lennox-Gastaut syndrome, migraine prophylaxis, and (with phentermine, as Qsymia) chronic weight management. Used as the canonical multifactorial anticonvulsant and as a reference carbonic anhydrase inhibitor in CNS pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-245Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vigabatrin

Plain-language summaryIntrigue 69 / 100

Vigabatrin (Sabril) is a so-called suicide inhibitor of GABA transaminase, the enzyme that breaks down the brain’s main inhibitory neurotransmitter. The vinyl group on the molecule converts vigabatrin into a fake substrate that the enzyme attempts to process and is then permanently destroyed by; the only way the brain restores normal GABA breakdown is to manufacture new enzyme from scratch. The result is sustained and powerful elevation of brain GABA levels. It is uniquely effective in infantile spasms (a devastating early-childhood seizure disorder) and refractory complex partial seizures. The catch is severe and irreversible: roughly a third of patients develop permanent visual field constriction from retinal toxicity. That has restricted it to cases where no alternative works. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

The canonical irreversible GABA-T suicide inhibitor, clinically validated but mechanistically mature and toxicity-constrained

Vigabatrin has been in the clinic since 1989 in Europe, with US approval following in 2009. That timeline matters for how you read the score. This isnt a compound at the frontier of anything; it’s a compound that already did its frontier work decades ago and has been in routine use ever since.

The mechanism is genuinely clever, and worth understanding on its own terms. The vinyl group at the alpha-carbon turns vigabatrin into a substrate that GABA transaminase begins to process but can’t release. The result is irreversible covalent inactivation of the enzyme, with GABA degradation capacity only restored by de novo enzyme synthesis. That makes the pharmacodynamic window substantially longer than the plasma half-life of 5 to 13 hours would suggest. As a piece of chemical biology, suicide inhibition is elegant; as a research tool, the irreversibility is actually useful for experiments requiring sustained, stable GABA-T suppression without continuous re-dosing.

The clinical translational story is real and worth acknowledging directly. For infantile spasms, specifically West syndrome, the treatment options are limited and vigabatrin is one of them. The UKISS trial and the pivotal FDA registration studies, particularly for tuberous sclerosis-associated spasms, showed meaningful seizure suppression where many anticonvulsants fail. That’s a durable human signal, not a preclinical artifact.

The problem, and it’s not a minor one, is the retinal toxicity. Bilateral concentric visual field constriction in roughly 30 to 50 percent of long-term users. Irreversible. The FDA REMS program exists because of this, mandating baseline and periodic visual field testing. Current research thinking attributes the damage to GABA accumulation in retinal photoreceptors. For bench investigators, this means any animal model work with vigabatrin has to account for retinal off-target effects as a confound.

We think vigabatrin earns a library spot specifically as a reference probe. If your research program touches GABA metabolism, inhibitory circuit modulation, or mechanism-based enzyme inhibition as a chemical strategy, vigabatrin is the standard. No other approved compound does what it does to GABA-T. What it doesnt offer is novelty, a growing literature edge, or any real frontier signal. The mechanistic questions are settled, the clinical niche is narrow, and the toxicity profile constrains enthusiasm for new indication discovery. A serious bench scientist working on GABAergic biology needs this compound; a scientist looking for their next interesting target probably doesnt start here.

Novelty

22

Mechanism promise

42

In-category differentiation

60

Evidence quality

76

Translational signal

70

Research bench value

65

Rationale Vigabatrin earns solid evidence and translational scores given FDA approval, REMS-backed safety surveillance, and real infantile spasms efficacy, but novelty is low for a compound with 35-plus years of literature and a fully characterized mechanism; primary research value now sits in its role as the definitive irreversible GABA-T probe for GABAergic circuit and enzyme kinetics work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA transaminase inhibitor (irreversible)

An irreversible suicide inhibitor of GABA transaminase; uniquely effective in infantile spasms and refractory complex partial seizures, limited by retinal toxicity.

Abstract

Vigabatrin ((R/S)-4-aminohex-5-enoic acid; CAS 60643-86-9; molecular formula C6H11NO2; molecular weight 129.16) is a vinyl-GABA suicide inhibitor of GABA transaminase developed at Marion Merrell Dow and approved by the FDA in 2009 under the trade name Sabril (later than European registration in 1989). Mechanism: the vinyl group at the alpha-carbon converts vigabatrin into a substrate that the GABA transaminase enzyme begins to process but cannot release; the result is irreversible covalent enzyme inactivation, requiring de novo enzyme synthesis to recover GABA degradation capacity. The consequence is sustained elevation of brain GABA concentrations. Effective in infantile spasms (West syndrome) where conventional anticonvulsants often fail, and as adjunctive therapy in refractory complex partial seizures. The principal limitation is irreversible bilateral concentric visual field constriction in approximately 30 to 50 percent of long-term users, attributed to retinal photoreceptor damage; the FDA REMS program requires baseline and periodic visual field assessment. Plasma half-life is 5 to 13 hours, but the irreversible enzyme inhibition produces effective activity beyond the plasma window. Used as the canonical GABA transaminase suicide inhibitor.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-246Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Buspirone

Plain-language summaryIntrigue 60 / 100

Buspirone (BuSpar) is the first non-benzodiazepine anxiolytic, approved by the FDA in 1986. Mechanistically it is unrelated to any sedative class: it is a partial agonist at the serotonin 5-HT1A receptor, with no GABA-A activity. That means it does not produce sedation, dependence, or withdrawal, and it has no recreational potential. The trade-off is that it works slowly (effects build over 2 to 4 weeks) and does not produce the fast acute relief patients expect from a benzodiazepine, which has limited its uptake despite its safety advantages. It is FDA-approved for generalized anxiety disorder and is widely used as add-on for SSRI-treated depression where some additional anxiolysis is needed. The active metabolite 1-PP is an alpha-2 antagonist contributing to the noradrenergic tone. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Canonical 5-HT1A probe, mature anxiolytic with real evidence but thin novelty in 2026

Look, buspirone is a compound that was genuinely interesting in 1986. The first non-benzodiazepine anxiolytic approved by the FDA, it demonstrated that you could hit generalized anxiety disorder through 5-HT1A partial agonism rather than GABA-A potentiation, and that doing so meant no sedation, no tolerance, no physical dependence. For its era, that was a meaningful pharmacological statement. The mechanism story around autoreceptor desensitization, where the delayed anxiolytic onset (two to four weeks) reflects slow downregulation of presynaptic 5-HT1A somatodendritic autoreceptors, remains instructive for anyone studying serotonin system kinetics. The 1-PP metabolite’s alpha-2 antagonism adds a noradrenergic wrinkle that still gets cited in systems-level work.

The problem is that we’re rating research merit in 2026, not 1986. The 5-HT1A partial agonist mechanism is thoroughly mapped. There are no hidden pockets in this pharmacology waiting to be discovered by a bench investigator picking up buspirone today. Its Ki of approximately 21 nM and intrinsic activity around 35 percent are numbers that have appeared in textbooks for decades. Secondary D2 antagonism at roughly 100 nM is real but the clinical significance remains unclear after forty years of trying to pin it down. Thats not the profile of a compound that’s going to generate an interesting paper in 2026 unless you’re specifically using it as a reference probe.

And that’s honestly where buspirone still earns its keep. As the canonical 5-HT1A partial agonist, it is the go-to tool compound when you need to isolate this receptor’s contribution to a behavioral or neurochemical readout. Comparing full agonists, partial agonists, and antagonists at 5-HT1A? You’re reaching for buspirone. Disentangling 5-HT1A from 5-HT1B or 5-HT2A contributions in a circuit-level experiment? Buspirone is in the protocol. That probe value is real, particularly in translational anxiety models or serotonin-system interaction studies. It’s not a replacement for newer tools, but it’s not obsolete either.

What we don’t find compelling is the idea of prioritizing buspirone as a primary research target. Its evidence base is among the strongest in this library, multiple phase 3 RCTs, decades of replicated mechanism work, FDA approval since Reagan’s second term. But that evidence bulk is exactly the problem: the question has been answered. GAD pharmacology has moved on to SSRIs, SNRIs, and increasingly ketamine and psychoplastogen-adjacent compounds as the interesting frontier. Buspirone sits comfortably in the literature as a mature reference standard with modest differentiation from newer anxiolytics on actual clinical metrics. Score it accordingly.

Novelty

22

Mechanism promise

30

In-category differentiation

35

Evidence quality

72

Translational signal

65

Research bench value

60

Rationale Buspirone earns its score almost entirely from evidence quality, translational signal, and residual bench utility as the reference 5-HT1A partial agonist; novelty and mechanism promise are dragged down by 40 years of literature and a single-receptor story that the field has well characterized. No scheduling or category cap applies, but the raw calculation lands squarely in established-mature territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist anxiolytic

An azapirone 5-HT1A partial agonist; a non-benzodiazepine anxiolytic without dependence or sedation.

Abstract

Buspirone (8-[4-(4-pyrimidin-2-yl-1-piperazinyl)butyl]-8-azaspiro[4.5]decane-7,9-dione; CAS 36505-84-7; molecular formula C21H31N5O2; molecular weight 385.50) is an azapirone 5-HT1A partial agonist developed at Bristol-Myers Squibb and approved by the FDA in 1986 under the trade name BuSpar. The compound is the first clinically approved non-benzodiazepine anxiolytic, distinguished by mechanism (5-HT1A partial agonism rather than GABA-A potentiation), tolerance/dependence profile (none), and absence of sedation. 5-HT1A affinity is approximately 21 nM (intrinsic activity approximately 35 percent); secondary D2 antagonism (Ki approximately 100 nM) is of unclear clinical significance. The active metabolite 1-(2-pyrimidinyl)piperazine (1-PP) is an alpha-2 adrenergic antagonist contributing to noradrenergic effects. Onset of anxiolytic effect is delayed (2 to 4 weeks), reflecting the time course of 5-HT1A autoreceptor desensitization. Plasma half-life is 2 to 3 hours; metabolism is extensive via CYP3A4 with significant first-pass effect (oral bioavailability approximately 4 percent). Approved for generalized anxiety disorder. Used as the canonical 5-HT1A partial agonist in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-248Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tandospirone

Plain-language summaryIntrigue 47 / 100

Tandospirone (Sediel, Senparen) is a Japanese-developed second-generation azapirone from Sumitomo, approved in Japan in 1996 and China in 2004. It has not been pursued in Western markets. Mechanistically it is closely related to buspirone, partially activating the serotonin 5-HT1A receptor, but with somewhat higher intrinsic activity at the receptor (around 60 percent versus buspirone’s 35 percent). Used for generalized anxiety and adjustment disorders, with some research interest in cognitive effects through 5-HT1A in the prefrontal cortex. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

31/100

A mature azapirone 5-HT1A partial agonist with narrow bench utility as a buspirone comparator

Look, tandospirone is a perfectly competent azapirone. Developed at Sumitomo, approved in Japan in 1996 and China in 2004, it does what the class does: partial agonism at 5-HT1A with a binding affinity around 27 nM and intrinsic activity in the 60 percent range. That last number is actually the most interesting thing about it. Buspirone, the dominant Western reference azapirone, sits closer to 40-45 percent intrinsic activity, so tandospirone offers a way to ask whether higher partial agonism translates to meaningfully better anxiolytic or antidepressant signal in a head-to-head experimental setup. Thats a real, answerable question.

The problem is that the question isnt very exciting anymore. 5-HT1A partial agonism has been studied relentlessly since buspirone hit the US market in 1986, and the clinical returns across the azapirone class have been modest. GAD is a genuine indication, but nothing in this receptor corner has broken out into something field-defining. Tandospirone’s clinical literature is almost entirely Japanese and Chinese, peer-reviewed but difficult to replicate in Western contexts, and the mechanistic work points back to the same receptor biology the field has understood for decades. The evidence base is real; it’s just mature.

Sourcing outside Japan and China is genuinely awkward. It’s not a Western research staple, which means the research-grade supply chain is thin compared to buspirone. We’ve seen this pattern with other Asian-market approvals where Western labs end up defaulting to the more available analog because sourcing friction outweighs the marginal mechanistic difference. The active metabolite 1-PP is also shared across azapirones, which can muddy interpretation when you’re trying to attribute effects specifically to the parent compound versus class-level pharmacology.

What we think: tandospirone has a narrow legitimate use case as a reference compound when 5-HT1A intrinsic activity gradations genuinely matter to your experimental design. If you’re constructing a dose-response curve across the partial agonism range and need something between buspirone and a full agonist, tandospirone fills that slot. But thats a specific niche, not a broad research program. The compound isn’t overhyped, it isn’t disproven, it just lives in a thoroughly mapped mechanistic corner of psychiatric pharmacology. For investigators interested in the serotonin receptor landscape from a fresh angle, the multi-target profile of something like vortioxetine or the ongoing work in 5-HT2A/1A crosstalk around psychoplastogens is where the real action is right now. Tandospirone belongs where the numbers put it: a serviceable reference tool in a class that ran out of frontier a long time ago.

Novelty

22

Mechanism promise

22

In-category differentiation

28

Evidence quality

48

Translational signal

42

Research bench value

35

Rationale Tandospirone is a 30-year-old Asian-market anxiolytic in a thoroughly characterized receptor class; its only differentiating feature is marginally higher 5-HT1A intrinsic activity than buspirone, giving it a narrow reference-tool use case but no serious novelty or mechanistic frontier value. Evidence is real but geographically concentrated and non-paradigm-shifting, placing it firmly in piracetam territory on the overall scale.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist anxiolytic (Asian markets)

A second-generation azapirone 5-HT1A partial agonist marketed in Japan and China; not approved in Western markets.

Abstract

Tandospirone ((1R,2R,6S,7S)-4-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]butyl})-4-azatricyclo[5.2.1.02,6]decane-3,5-dione; CAS 87760-53-0; molecular formula C21H29N5O2; molecular weight 383.49) is a second-generation azapirone 5-HT1A partial agonist developed at Sumitomo and approved in Japan in 1996 (Sediel) and China in 2004 (Senparen). Receptor profile is closely related to buspirone: 5-HT1A affinity approximately 27 nM (intrinsic activity approximately 60 percent, higher than buspirone); minimal D2 affinity. Compared to buspirone, the higher 5-HT1A intrinsic activity is hypothesized to produce somewhat greater anxiolytic and antidepressant effect. Plasma half-life is approximately 1 hour; metabolism is via CYP3A4 with active metabolite 1-PP common to the azapirone class. Approved indications include generalized anxiety disorder and adjustment disorder with anxiety; off-label use in depression. Not approved in the US or EU. Used as a reference azapirone with higher 5-HT1A intrinsic activity than buspirone in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-249Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gepirone

Plain-language summaryIntrigue 64 / 100

Gepirone (Exxua) finally reached FDA approval in 2023, more than thirty years after its initial development at Bristol-Myers Squibb began in the 1980s. The 5-HT1A partial agonist had been rejected by the FDA multiple times before Fabre-Kramer eventually pushed an extended-release formulation across the finish line for major depressive disorder. The selling point versus standard SSRIs is essentially zero sexual dysfunction, which is the side effect that drives many patients off serotonergic antidepressants. Mechanistically it is in the same azapirone family as buspirone but with substantially more 5-HT1A intrinsic activity, which appears to translate into antidepressant rather than just anxiolytic effects. Real-world prescribing data are still accumulating. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

FDA-approved azapirone that took 30 years to clear; limited novelty for bench researchers in 2026

Look, gepirone is a compound with an unusual story: 30-plus years in development, multiple FDA rejections, and a 2023 approval under Exxua that felt more like the FDA eventually relenting than a decisive efficacy win. That history matters when you’re trying to figure out what this compound actually tells you.

The mechanism is 5-HT1A partial agonism, and if that sounds familiar, it should. Buspirone has been doing the same thing since 1986. Gepirone’s affinity sits around 19 nM with roughly 60 percent intrinsic activity and minimal D2 involvement, which is a slightly cleaner pharmacological profile than buspirone in some respects. The active metabolite 1-PP shares some alpha-2 receptor activity with buspirone’s 1-PP as well. The ER formulation is the real packaging innovation here, turning a three-times-daily regimen into once-daily dosing. But none of that adds up to a novel mechanism or a new research angle.

What gepirone has going for it clinically is the absence of sexual dysfunction. SSRIs are notorious for it, and a serotonergic antidepressant that sidesteps that tolerability liability is genuinely valuable in the clinic. Multiple phase 3 trials eventually demonstrated sufficient efficacy for MDD to clear the regulatory bar. That earns real evidence quality and translational signal scores, and those pull the overall number up from where novelty and mechanism alone would leave it.

Heres the thing for bench researchers, though: buspirone already exists as your 5-HT1A partial agonist reference compound. If you’re running a rodent depression or anxiety model and need a selective 5-HT1A partial agonist, gepirone offers marginal incremental probe value over buspirone, which is cheaper, better-characterized in animal models, and has four decades of comparative literature behind it. The gepirone advantage is the ER formulation and the cleaner D2 profile in humans; neither of those translates to bench utility in any meaningful way.

We dont think gepirone is a bad compound. The 2023 approval is real, the tolerability profile is a genuine clinical advance, and theres some value in a 5-HT1A partial agonist with a depression-focused regulatory history. But the mechanism is mature, the novelty is low, and the primary differentiation is a clinical tolerability story rather than a mechanistic one. A serious investigator running a 5-HT1A research program already has buspirone. Adding gepirone to that bench doesn’t open new questions. It confirms old answers in a slightly better-tolerated package.

Novelty

22

Mechanism promise

28

In-category differentiation

30

Evidence quality

58

Translational signal

62

Research bench value

35

Rationale Gepirone earns real points on evidence quality and translational signal from its 2023 FDA approval for MDD, but its mechanism is decades-old single-receptor 5-HT1A partial agonism with buspirone already serving as the reference probe; the 30-year regulatory slog reflects modest differentiation in a crowded space, leaving it a low-priority bench target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist

An azapirone 5-HT1A partial agonist developed for major depressive disorder; FDA-approved in 2023 after a 30-year development cycle.

Abstract

Gepirone (4,4-dimethyl-1-{4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}-2,6-piperidinedione; CAS 83928-76-1; molecular formula C19H29N5O2; molecular weight 359.47) is an azapirone 5-HT1A partial agonist developed by Bristol-Myers Squibb and Fabre-Kramer over a 30-plus-year development cycle, ultimately approved by the FDA in 2023 under the trade name Exxua for major depressive disorder. The compound is structurally and mechanistically similar to buspirone: 5-HT1A affinity approximately 19 nM with intrinsic activity approximately 60 percent; minimal D2 affinity; active metabolite 1-PP. Distinct from buspirone in development trajectory (positioned for depression rather than anxiety) and in being formulated as extended-release for once-daily dosing. The approved indication is MDD; the principal selling point versus SSRIs is absence of sexual dysfunction (a major SSRI tolerability complaint). Plasma half-life is 18 hours (ER formulation); metabolism is via CYP3A4. Used as a reference 5-HT1A partial agonist with depression-focused clinical development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-250Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pregabalin

Plain-language summaryIntrigue 67 / 100

Pregabalin (Lyrica) is a GABA look-alike that does not actually bind any GABA receptor or GABA transporter. Instead it binds the alpha-2-delta subunit of voltage-gated calcium channels, which reduces the release of glutamate and several other neurotransmitters at synapses. The compound came out of Northwestern University and was developed by Pfizer; the FDA approved it in 2004. It is widely used for neuropathic pain (diabetic neuropathy, postherpetic neuralgia), fibromyalgia, partial seizures, and generalized anxiety. Onset is rapid by anxiolytic standards (within hours to a few days). It produces euphoria in some patients and is a Schedule V controlled substance in the US owing to abuse potential, particularly in people with prior opioid or sedative use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

55/100

Canonical alpha-2-delta reference probe; mature approved drug with excellent evidence but low frontier research value

Look, pregabalin is a real drug. FDA-approved 2004, multiple confirmed indications, linear PK, Ki of roughly 22 nM at alpha-2-delta-1. The Silverman lab at Northwestern built something that actually works, and the clinical literature is not ambiguous. If you need a compound to establish alpha-2-delta subunit contribution in a pain or seizure model, pregabalin is what you reach for. That’s the honest case for having it in the library.

Here’s the thing though: when a compound has been FDA-approved for over two decades, that’s not a research signal, thats a research endpoint. The mechanism is thoroughly mapped. Presynaptic alpha-2-delta-1 binding reduces calcium influx, and downstream transmitter release (glutamate, norepinephrine, substance P, CGRP) drops accordingly. Elegant when it was first described. Now it’s a textbook entry. There’s no serious literature debate about what pregabalin does; the conversation moved on.

Differentiation within its class is real. Pregabalin has linear pharmacokinetics versus gabapentins notorious saturable absorption, and the potency advantage is meaningful (roughly three to four times more potent by binding affinity). So within the alpha-2-delta ligand family, it’s clearly the reference standard. But the alpha-2-delta class itself isn’t a frontier anymore. The interesting open questions in neuropathic pain and neuromodulation have migrated toward sodium channel isoform selectivity, glial targets, and dorsal horn circuit biology. Pregabalin doesn’t illuminate any of those questions.

The Schedule V status in the US reflects real, if modest, abuse liability. At supratherapeutic doses users describe benzodiazepine-like euphoria, which is mechanistically interesting but not research-interesting in the Kodiac sense. What we dont love is the positioning risk: this compound is well-known enough that investigators sometimes treat it as background infrastructure rather than an experimental variable, which tends to produce lazy study designs.

Where we think pregabalin earns its place is narrow and specific. If your research program needs to pharmacologically isolate alpha-2-delta subunit contributions from other calcium channel biology, pregabalin is the tool. Its bioavailability, linear kinetics, and established selectivity profile make it substantially cleaner than alternatives. That’s a real but circumscribed bench value. The evidence quality is outstanding because it’s an approved drug; the translational signal is excellent for the same reason. But those scores reflect a compound thats been characterized, not a compound worth characterizing. Score it accordingly.

Novelty

20

Mechanism promise

40

In-category differentiation

60

Evidence quality

82

Translational signal

80

Research bench value

70

Rationale Pregabalin scores well on evidence and translational signal because it is an approved drug with robust phase 3 data, but those same facts drag novelty and mechanism-promise to the floor. Its library value is almost entirely probe-based: if you are doing alpha-2-delta subunit biology, this is your reference ligand, and that earns it a real but modest score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Alpha-2-delta calcium channel ligand (GABA analog)

A GABA structural analog binding the alpha-2-delta subunit of voltage-gated calcium channels; approved for neuropathic pain, fibromyalgia, and partial seizures.

Abstract

Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid; CAS 148553-50-8; molecular formula C8H17NO2; molecular weight 159.23) is a GABA structural analog developed at Pfizer (Northwestern University origin, Lipton/Silverman) and approved by the FDA in 2004 under the trade name Lyrica. Despite the structural resemblance to GABA, the compound does not act on GABA-A, GABA-B, or GABA reuptake mechanisms; the molecular target is the alpha-2-delta-1 subunit of voltage-gated calcium channels, where high-affinity binding (Ki approximately 22 nM) reduces presynaptic calcium influx and consequent release of glutamate, norepinephrine, substance P, and CGRP. Plasma half-life is 6.3 hours; renal excretion is the principal clearance pathway with linear pharmacokinetics. Approved indications include neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, partial-onset seizures (adjunctive), and generalized anxiety disorder (in EU). The compound has scheduled status (Schedule V in the US) reflecting modest abuse potential at supratherapeutic doses, where users report euphoria and benzodiazepine-like effects. Used as the canonical alpha-2-delta calcium channel ligand reference.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-251Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gabapentin

Plain-language summaryIntrigue 65 / 100

Gabapentin (Neurontin) is the older sibling of pregabalin from Parke-Davis, FDA-approved in 1993, and it works by the same mechanism: binding the alpha-2-delta subunit of voltage-gated calcium channels, with no actual effect on GABA receptors despite the misleading name. The big practical difference from pregabalin is dose-response: gabapentin’s intestinal absorption saturates, so doubling the dose does not double the blood level, which makes high doses inefficient. Approved for postherpetic neuralgia and partial seizures, with massive off-label use for anxiety, sleep, alcohol withdrawal, restless legs, and chronic pain. The Pfizer off-label marketing campaign that drove its sales in the 1990s was the subject of a landmark fraud settlement. Abuse potential is real but lower than pregabalin’s. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Mature alpha-2-delta ligand superseded by pregabalin clinically; still a clean reference probe for VGCC subunit biology

Look, gabapentin has been in the literature since 1993 and the research community has had more than three decades to extract novelty from it. For a bench scientist asking what deserves time right now, this isn’t the answer. But thats not the same as saying it has no place in the library.

The mechanism is genuinely specific: gabapentin binds the alpha-2-delta-1 subunit of voltage-gated calcium channels with a Ki of roughly 80 nM. Despite the name, it has no meaningful activity at GABA-A or GABA-B receptors. What it does is reduce presynaptic calcium influx and downstream neurotransmitter release at sensitized synapses. That mechanism is clean and validated across hundreds of independent studies. The problem is that everyone already knows this. The pharmacology has been squeezed for novelty and the returns have diminished sharply.

What really sinks it as a frontier research target is the pharmacokinetics combined with the availability of better tools. Gabapentin relies on a saturable intestinal transporter for absorption. Bioavailability can hit 80 percent at low doses and collapse to around 27 percent at 1600 mg, producing nonlinear dose-response and frustrating individual variability in clinical work. Pregabalin solved that transporter saturation problem and achieved linear absorption, which is a large part of why it has displaced gabapentin in most new pharmacological programs. If you need a selective alpha-2-delta-1 ligand for a clean assay, you have options and some are meaningfully better.

The clinical evidence base is real and substantial. Multiple large phase 3 trials, FDA approval for postherpetic neuralgia and partial-onset seizures, and an extensive off-label literature covering neuropathic pain broadly, anxiety, alcohol withdrawal, and restless legs syndrome. We don’t find the off-label literature particularly compelling as a research signal. Much of it is small-N, inconsistent in methodology, and complicated by the well-documented history of off-label promotion litigation against Pfizer. The clean translational signal sits in the original approved indications.

As a probe, gabapentin still earns its keep in a narrow context. If you’re studying alpha-2-delta-1 subunit trafficking, presynaptic calcium dynamics in dorsal root ganglia, or the molecular basis of central sensitization, gabapentin is the reference ligand. The literature density means any result you generate is immediately contextualizable. For that specific utility, we actually think it belongs in the library.

What we don’t think is that it qualifies as interesting research territory. The real mechanistic questions in this space are being asked with more selective or structurally novel tools. Gabapentin functions like a positive control: necessary to have, not exciting to use. A score of 41 reflects exactly that balance, strong evidence and clinical history dragging up a compound with very little research novelty left in the tank.

Novelty

20

Mechanism promise

28

In-category differentiation

22

Evidence quality

72

Translational signal

68

Research bench value

55

Rationale Gabapentin scores low on novelty and differentiation because it is a 1993 approval with a well-understood mechanism and a clearly superior successor in most contexts; evidence and translational scores are pulled up by its approved-drug pedigree and large clinical dataset, while bench value is rescued by its canonical role as the alpha-2-delta-1 probe in seizure and pain pharmacology programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GABA analog calcium channel ligand

A GABA analog binding the alpha-2-delta subunit of voltage-gated calcium channels; the structural and clinical predecessor to pregabalin.

Abstract

Gabapentin (1-(aminomethyl)cyclohexaneacetic acid; CAS 60142-96-3; molecular formula C9H17NO2; molecular weight 171.24) is a GABA analog developed at Parke-Davis (Pfizer) in the 1980s and approved by the FDA in 1993 under the trade name Neurontin. Mechanism mirrors pregabalin: binding to the alpha-2-delta-1 subunit of voltage-gated calcium channels (Ki approximately 80 nM, weaker than pregabalin), reducing presynaptic neurotransmitter release. No direct GABA receptor activity. Plasma half-life is 5 to 7 hours. Distinguished from pregabalin by saturable absorption: oral bioavailability ranges from 80 percent at 100 mg to 27 percent at 1600 mg, producing nonlinear dose-response and unpredictable individual responses at higher doses. Approved for postherpetic neuralgia and partial-onset seizures (adjunctive); off-label use is extensive (anxiety, alcohol withdrawal, restless legs syndrome, hot flashes, hiccups, neuropathic pain of all causes, migraine prophylaxis). The compound has been the subject of extensive off-label promotion litigation and is now scheduled in some US states reflecting abuse potential. Used as the canonical alpha-2-delta-1 calcium channel ligand and a reference compound in seizure pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-252Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hydroxyzine

Plain-language summaryIntrigue 56 / 100

Hydroxyzine (Atarax, Vistaril) is a first-generation antihistamine from UCB, approved in 1956, that crosses the blood-brain barrier readily and produces sedation and anxiolysis as a result. It is FDA-approved for anxiety and pruritus (itching), and unlike benzodiazepines it has no dependence or withdrawal potential, which makes it a useful first-line option for situational anxiety in patients with substance use histories. The trade-off is that the same antihistamine and anticholinergic effects produce dry mouth, constipation, urinary retention, and next-day grogginess. The active leftover after liver metabolism is cetirizine (Zyrtec), the over-the-counter allergy drug, which does not cross into the brain at clinical doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A 1956-approved FDA drug with solid clinical evidence and essentially no research frontier left to explore

Look, hydroxyzine is a real drug. FDA approved in 1956, over a billion patient-exposures, solid randomized data for generalized anxiety and pruritus, a clean non-scheduled status that made it clinically useful before buspirone or the SSRIs arrived. We’re not dismissing it clinically. We’re saying there’s almost nothing here for a bench investigator in 2026 that hasn’t been settled for decades.

The mechanism is H1 antagonism at roughly 2 nM affinity, secondary 5-HT2A blockade around 10 nM, and a weak D2 component. That multi-receptor fingerprint is interesting in the abstract, but it’s fully mapped, well-understood, and not pointing at anything new. The 5-HT2A angle doesn’t give you psychoplastogen biology; the D2 component isn’t the basis for a new antipsychotic story. You’re reading 1980s receptor binding papers when you go looking for mechanism literature here.

What’s genuinely useful about hydroxyzine as a research tool is the metabolite relationship. Hydroxyzine produces cetirizine in vivo, and cetirizine loses CNS penetration because of the carboxylic acid group. That pairing has been used as a probe model to interrogate what H1-mediated CNS penetration actually contributes versus peripheral H1 blockade. Thats a narrow but real utility. If you’re building a pharmacokinetic or CNS-penetration model around first-generation antihistamines, hydroxyzine earns a seat at the table. For anything else, it doesn’t.

The evidence base is strong by the standards of research compounds. Multiple replicated RCTs across anxiety and pruritus indications, decent Hamilton Anxiety Rating Scale data, perioperative sedation trials. The HAMA studies from the 1970s through the 1990s were reasonably well-designed for their era. You’re not dealing with single-lab preclinical data and Croatian rodent models here. But strong evidence for a fully-characterized approved drug is actually the least interesting kind of strong evidence when you’re trying to identify what to study next.

We don’t see a compelling frontier angle. The anxiolysis mechanism isn’t being revisited in a new light. The H1 space isn’t generating exciting new biology. The drug’s non-controlled status is a clinical feature, not a research opportunity. If your program touches first-gen antihistamines as comparators or pharmacokinetic probes, hydroxyzine is a reasonable tool to have documented. As a primary research target in its own right, honestly, you’re working from a 1956 foundation with nowhere obvious to go.

Novelty

12

Mechanism promise

22

In-category differentiation

32

Evidence quality

68

Translational signal

65

Research bench value

45

Rationale Hydroxyzine scores low on novelty and mechanism because it’s a 70-year-old approved drug with a fully characterized H1/5-HT2A/D2 profile; the high evidence and translational scores reflect its genuine approved-drug trial base, but those can’t rescue the overall when the compound offers nothing a serious investigator hasn’t seen. Bench value gets a modest credit for its canonical probe role comparing CNS-penetrant vs. non-penetrant antihistamine effects via its cetirizine metabolite relationship.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation H1 antihistamine anxiolytic

A first-generation piperazine H1 antihistamine with anxiolytic activity; the first non-controlled anxiolytic widely used in psychiatry.

Abstract

Hydroxyzine (2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol; CAS 68-88-2; molecular formula C21H27ClN2O2; molecular weight 374.91) is a first-generation piperazine H1 antihistamine developed at UCB and approved by the FDA in 1956 under the trade names Atarax and Vistaril. Distinct from later antihistamines by clinically significant CNS penetration, producing the sedation and anxiolytic effects characteristic of first-generation H1 blockers. H1 affinity approximately 2 nM; secondary 5-HT2A antagonism (Ki approximately 10 nM) and weak D2 antagonism contribute to the anxiolytic profile. The principal active metabolite cetirizine retains H1 antagonism but loses CNS penetration owing to addition of a carboxylic acid group, and is marketed separately as a non-sedating antihistamine (Zyrtec). Plasma half-life is 14 to 25 hours; metabolism is hepatic. Approved for anxiety, pruritus, and as a preoperative sedative; off-label use in insomnia and as a benzodiazepine-sparing anxiolytic. Used as the canonical first-generation H1 antihistamine in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-253Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Gaboxadol (THIP)

Our opinion on this compoundNiche research probe

61/100

The canonical extrasynaptic delta-GABA-A probe; therapeutically abandoned but mechanistically irreplaceable for tonic inhibition research

Look, gaboxadol is a weird one to rate because it exists in two completely separate stories simultaneously. The first story is a clinical failure: Lundbeck and Merck took it through Phase 3 in primary insomnia, watched patients experience disorientation and hallucinations, and pulled the plug in 2007. That story is over. The second story is the interesting one, and its the reason gaboxadol belongs in this library at all.

Here’s the thing about the mechanism. Most GABA pharmacology targets synaptic receptors, the alpha1/2/3-beta-gamma2 isoforms that benzodiazepines and z-drugs hit. Those receptors mediate phasic inhibition, fast transient signals. Gaboxadol does something different: it’s a superagonist at extrasynaptic GABA-A receptors bearing the delta subunit, primarily alpha4-beta3-delta and alpha6-beta3-delta, and those receptors mediate tonic inhibition, the continuous low-amplitude background current that sets the excitability baseline of a neuron. Thats a genuinely different biological variable, and most of the GABA pharmacology toolkit doesn’t let you isolate it cleanly.

We think the differentiation here is underappreciated. Muscimol hits both synaptic and extrasynaptic receptors indiscriminately. DS2, a delta-selective PAM, modulates the receptor but doesn’t agonize it directly. If you want to study what delta-subunit tonic GABA-A current actually does in a circuit, gaboxadol is effectively the only clean pharmacological lever. That’s a real niche, and it’s gotten more interesting since the brexanolone and zuranolone data validated the delta-subunit angle for neurosteroid-sensitive states. Labs working on PMDD biology, alcohol use disorder, stress-related changes in inhibitory tone, or sleep architecture at the subunit level are going to want this compound on the shelf.

The evidence picture is decent for a failed drug. Multiple Phase 3 trials ran to completion before the adverse event signal emerged. That means there’s actual human pharmacology data: real EEG effects, real sleep architecture changes, real CNS penetration confirmed by the adverse events themselves. Preclinical literature is solid and multi-lab. The translational signal is real but it points toward a wall therapeutically, which is why the score here isn’t higher overall.

Honestly, if you’re not working on GABA-A subunit biology specifically, this compound probably isn’t your priority. The clinical failure isn’t a reason to ignore it, but it does mean the research community actively using it is a specialist one. For those investigators, it’s close to indispensable. For everyone else, it’s a footnote in GABA pharmacology history with a genuinely interesting mechanism they probably won’t have occasion to use.

Novelty

48

Mechanism promise

68

In-category differentiation

72

Evidence quality

60

Translational signal

45

Research bench value

75

Rationale Gaboxadol failed Phase 3 as a hypnotic due to adverse psychiatric events, but the mechanism is intact and validated; it scores high on differentiation and bench value because no other compound selectively probes extrasynaptic delta-containing GABA-A receptors with the same precision, making it indispensable for labs working on tonic inhibition, neurosteroid sensitivity, or delta-subunit biology specifically.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective extrasynaptic GABA-A delta-subunit agonist

A 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol agonist selective for extrasynaptic GABA-A receptors containing the delta subunit; investigated as a hypnotic.

Abstract

Gaboxadol (THIP; 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; CAS 64603-91-4; molecular formula C6H8N2O2; molecular weight 140.14) is a selective extrasynaptic GABA-A receptor agonist developed at Lundbeck and Merck through the 1990s and 2000s. Distinct from benzodiazepines and barbiturates by selective binding to GABA-A receptor isoforms containing the delta subunit (alpha4-beta3-delta and alpha6-beta3-delta), which are predominantly extrasynaptic and mediate tonic (continuous, low-amplitude) inhibition rather than the phasic (high-amplitude, transient) inhibition mediated by synaptic alpha1/2/3-beta-gamma2 receptors. The compound is a superagonist at delta-containing receptors (efficacy greater than that of GABA itself). Phase 3 trials in primary insomnia (2007) were halted following adverse psychiatric events including disorientation and hallucinations; development was abandoned. The compound retains research utility as the canonical extrasynaptic delta-GABA-A agonist for academic GABA pharmacology and sleep architecture studies. Plasma half-life is approximately 1.5 to 2 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-255Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tofisopam

Plain-language summaryIntrigue 56 / 100

Tofisopam (Grandaxin) is an unusual benzodiazepine from EGIS in Hungary, registered in the 1960s. The chemistry is technically a benzodiazepine, but the substitution pattern (a 2,3-fused ring rather than the standard 1,4-fused ring of diazepam and lorazepam) means it does not bind the classic GABA-A benzodiazepine site at all. As a result it produces anxiolysis without sedation, muscle relaxation, cognitive impairment, or dependence. The actual mechanism is not fully worked out, with proposals including phosphodiesterase inhibition and dopaminergic modulation. Approved across Europe and parts of Asia for anxiety and autonomic dysfunction; never approved in the US. Genuinely interesting pharmacologically because it shows that the benzodiazepine scaffold can do more than activate GABA-A. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

51/100

A structurally distinct non-GABA-A anxiolytic with real probe value and an incompletely mapped mechanism worth investigating

Here’s the thing about tofisopam: it’s not a benzodiazepine in the way that word usually lands. Yes, the diazepine ring is there, but the nitrogen positions are at the 2,3 carbons rather than the 1,4 positions of diazepam or lorazepam, and that single structural difference eliminates binding at the classical benzodiazepine allosteric site on GABA-A receptors entirely. That means no sedation from GABA current potentiation, no muscle relaxation from that pathway, and by most accounts no physical dependence profile that mirrors classical benzos. EGIS Pharmaceuticals in Hungary developed it in the 1960s, and it’s been marketed as Grandaxin in Hungary, France, and several Asian markets for decades under indications that include anxiety, autonomic instability, and post-stress recovery. For a compound this old to still have an incompletely characterized mechanism is either a red flag or a research opportunity depending on how you look at it.

We lean toward opportunity, cautiously. The leading hypotheses for tofisopam’s activity include phosphodiesterase IV (PDE4) inhibition and some form of dopaminergic modulation, possibly both operating in parallel. PDE4 inhibition is not a trivial mechanism: roflumilast got approved for COPD on that axis, and the neuroimmune and cognitive implications of PDE4 in the CNS have attracted serious attention over the last decade. If tofisopam genuinely hits PDE4 with relevant potency in neural tissue, thats a more interesting story than it usually gets credit for. The dopaminergic angle is less characterized but could explain the reported antifatigue and mood-brightening effects that dont fit a pure anxiolytic profile. What we dont have is a clean pharmacological dissection confirming which target drives which effect at clinically relevant concentrations.

The evidence base is the main drag on the score. Tofisopam has human approval, which is real, but the supporting literature is heavily weighted toward Eastern European clinical work from the 1970s through the 1990s, published in journals that dont make modern replication standards easy to verify. There isnt a modern phase 2 or phase 3 RCT benchmarking it against placebo or active comparators with current methodology. The preclinical literature is sparse compared to what you’d want before building a research program around it.

Where tofisopam earns its keep is as a reference tool. If your lab is trying to understand what non-GABAergic, non-serotonergic anxiolysis looks like pharmacologically, it’s essentially the only 2,3-benzodiazepine with a usable human history and commercial availability. That niche is real but narrow. Honestly, it scores where it scores because it’s genuinely interesting as a probe without being important enough in any active research conversation to rank higher. Investigators in autonomic pharmacology or PDE4 neuroimmunology should know it exists.

Novelty

42

Mechanism promise

55

In-category differentiation

60

Evidence quality

40

Translational signal

48

Research bench value

60

Rationale Tofisopam’s 2,3-benzodiazepine scaffold genuinely sidesteps classical GABA-A activity, making it the reference probe for non-sedating, non-dependence-forming anxiolysis via a mechanism that still isn’t fully nailed down; the European approval provides a real human signal, but the evidence base is dominated by older Eastern European literature with limited modern replication, keeping differentiation and bench value from pulling the score higher.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

2,3-benzodiazepine atypical anxiolytic

A 2,3-benzodiazepine without classical GABA-A activity; a non-sedating anxiolytic marketed in Europe.

Abstract

Tofisopam (1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; CAS 22345-47-7; molecular formula C22H26N2O4; molecular weight 382.46) is a 2,3-benzodiazepine developed at EGIS (Hungary) in the 1960s and approved in Hungary, France, and other European and Asian markets under the trade name Grandaxin. Distinct from the 1,4-benzodiazepine class (diazepam, lorazepam, etc.) by the position of the nitrogens in the diazepine ring: the 2,3 isomer does not bind the classical benzodiazepine site on GABA-A receptors and lacks the GABA-A-mediated sedation, anxiolysis, and dependence of conventional benzodiazepines. The mechanism is incompletely characterized; possibilities include phosphodiesterase IV inhibition and modulation of dopaminergic signaling. Plasma half-life is approximately 6 to 8 hours; metabolism is hepatic. Approved indications in markets where registered include anxiety disorders, autonomic instability, and post-stress recovery; off-label use in fatigue and reactive depression. Not approved in the US. Used as a reference 2,3-benzodiazepine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-254Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 60 61 62 63 64 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.